Cannabis Science Presents Newest Case Photos of the 3rd Critical Squamous Cell Carcinoma Self-Medicated Cannabis Patient with...
February 23 2012 - 11:34AM
Business Wire
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S.
biotech company developing pharmaceutical cannabis (marijuana)
products is monitoring the outstanding progress of the 3rd
Self-Medicated Cannabis Patient with Clear Continued Improvement.
This self-medicating patient has what his doctors describe as the
worst case of squamous cell carcinoma the had ever seen. This
patient’s tumors, while resistant to conventional treatment,
continues to make obvious improvement with the use of cannabis
extracts.
Figure 1 shows the tumor from the last treatment on the left
side of the patient’s head, scabbing over and healing. A cavernous
opening began to form, and the roof and sides of the tumor have
degraded and fallen off, as shown in Figure 2. Figures 3 and 4 show
the tumor from above, and it is clear that the tumor continues to
degrade.
On the right side of the patient’s head, the tumor is also
slowly healing from the application of the cannabis-based extracts.
The last three pictures show the absorption and killing of the
tumor by the extract.
You can view these graphic photos on the Cannabis Science
website www.cannabisscience.com and click the button “View Images
of 3rd Self-Medicated Patient & His Apparent Success.”
Cannabis Science continues to focus on cancer as a major initial
target for treatment with its critical ailment formulations.
Cannabis Science has provided the scientific foundation for
numerous patients suffering from cancer to make the informed
decision to treat themselves with cannabis extracts. The company
has seen vast improvement in four out of patients with skin cancer
to date who we have been scientifically advising. Their
photo-documentation is available on the Cannabis Science website
www.cannabisscience.com and click on the breaking news button where
you will find all the cancer related and updated patient news.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.